Shares of Cronos Group Inc. (CRON) surged 5.24% in pre-market trading on Thursday following the release of the company's impressive second quarter 2025 financial results. The cannabis company reported significant growth in revenue and profitability, driven by strong international performance and operational improvements.

Cronos announced that net revenue for Q2 2025 increased by 21% year-over-year to $33.5 million. The company achieved record sales from Cronos Israel and continued momentum in international markets. Gross profit more than doubled to $14.5 million, with gross margin expanding to 43% from 23% in the same period last year. Adjusted EBITDA turned positive at $1.7 million, compared to a loss of $11.1 million in Q2 2024.

Key highlights from the earnings report include: - Highest-ever international and Israel revenue, with the PEACE NATURALS brand maintaining its position as the top cannabis brand in Israel - Successful expansion into new medical cannabis markets, including Australia, Malta, and Switzerland - Completion of the Cronos GrowCo expansion, expected to fuel growth in both international and domestic Canadian markets - A strong balance sheet with $834 million in cash and short-term investments Mike Gorenstein, Chairman, President and CEO of Cronos, commented on the results: "Cronos delivered another quarter of strong performance, highlighted by record sales from Cronos Israel and continued momentum in international markets. Our strength abroad has been instrumental in driving meaningful margin improvement, underscoring the benefits of our global strategy."